Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD Authors: Bafadhel M, Greening N, Harvey-Dunstan T, et al. Chest 2016; 150: 320-328 Summary: The current treatment of chronic obstructive pulmonary disease (COPD) exacerbations includes systemic steroids, antibiotics or both. There is evidence that patients with eosinophilic, moderate-severity exacerbations (eosinophil cell count >2% of white blood cells) have better steroid response.
This study recruited subjects from a randomised clinical trial of an exercise-based recovery intervention. 243 patients with a smoking history of >10 pack-years with the diagnosis of COPD were enrolled. All patients had full blood counts on admission. Peripheral eosinophilia was observed in 25% of subjects (n=62, peripheral blood count >200 cells per μL or >2% of leukocytes). Patients with eosinophilia had a significantly lower C-reactive protein (CRP) (median (interquartile range) 13 (5-48) versus 55 (18-139) mg⋅dL −1 , p<0.001) and significantly shorter hospital stay compared to neutrophilic patients after corticosteroid treatment (mean (range) 5.0 (1-19) versus 6.5 (1-33) days, p<0.015). 69 patients had evidence of consolidation on chest radiography. After exclusion of these patients, CRP was still significantly lower in patients with eosinophilia. Pre-admission corticosteroid treatment had no significant effect on hospital stay.
In conclusion, eosinophilia can be identified in 25% of patients with COPD exacerbations. These patients have a higher risk of harm without systemic steroid treatment. As this study was a post hoc analysis, further studies are needed to corroborate the results. ) for small cell lung cancer (SCLC). The models were based either on the insertion of a clinically relevant point mutation (Kras LSL-G12D and Egfr
L858R
) or knock-out of the tumorsuppressor genes Trp53 or Rb1. Overall, the immune response, as measured by the leukocyte (CD45 + cell) content in the tumor, was lower in SCLC compared to NSCLC in both animal models and human tissues. Most notably for adenocarcinomas, the Egfr-mutant to hospital or died within 90 days of discharge. They identified five independent predictors of need for readmission or death within 90 days. This led to development of the PEARL prognostic score comprising five indices: previous admissions (severe exacerbation in the past year), extended Medical Research Council dyspnoea score, age, right-sided heart failure and left-sided heart failure. The authors showed that this score is a consistent and accurate predictor of 90-day readmission or death. Higher PEARL scores were associated with a shorter time to readmission. The area under receiver operator characteristic curve for 90-day readmission/death without readmission was shown to be 0.70, which is superior to other scores that have been used in this population such as ADO (age, dyspnoea and airflow obstruction), BODEX (body mass index, airflow obstruction, dyspnoea and exacerbations), DOSE (dyspnoea, obstruction, smoking and exacerbation) and LACE (length of stay, acuity of the admission, comorbidity and emergency department use).
The authors conclude that PEARL score is easy to apply at the bedside using indices that are routinely available in all patients and accurately risk stratifies patients according to risk of readmission. This score may be useful to inform post-discharge planning in patients admitted with acute exacerbation of COPD. 
